Long-Term Outcomes of Recipients of Liver Transplants from Living Donors Treated with a Very Low-Calorie Diet
Table 2
Recipient baseline characteristics.
n = 199
Non-VLCD recipient n = 165
VLCD recipient n = 34
P value
Sex, female, n (%)
83 (50.6%)
13 (38.2%)
0.3
Age at transplant (years), median (IQR)
55 (45–63)
59 (46–64)
0.4
Primary diagnosis, n (%)
0.9
Primary sclerosing cholangitis
39 (23.6%)
8 (23.5%)
SLD
33 (20%)
8 (23.5%)
B or C hepatitis
27 (16.4%)
7 (20.6%)
Hepatocellular carcinoma
8 (4.9%)
0 (0%)
Autoimmune hepatitis
13 (7.9%)
2 (5.9%)
Alcohol liver cirrhosis
19 (11.5%)
6 (17.7%)
Fulminant hepatitis
2 (1.2%)
0 (0%)
Retransplant
1 (0.6%)
0 (0%)
Others†
23 (13.9%)
1 (2.9%)
Secondary diagnosis, n (%)
0.5
None
104 (63%)
21 (61.8%)
Primary sclerosing cholangitis
3 (1.8%)
0 (0%)
SLD
6 (3.6%)
0
B or C hepatitis
2 (1.2%)
0
Hepatocellular carcinoma
40 (24.2%)
9 (26.5%)
Autoimmune hepatitis
2 (1.2%)
0
Alcohol liver cirrhosis
7 (4.2%)
3 (8.8%)
Others†
1 (0.6%)
1 (2.9%)
AST before LT (IU/L), median (IQR)
53 (35–92)
52.5 (35–73)
0.6
ALT before LT (IU/L), median (IQR)
33 (20–58)
33.5 (25–67)
0.6
Total bilirubin before LT (μmol/L), median (IQR)
48 (24–88)
43 (18–77)
0.5
INR before LT, median (IQR)
1.4 (1.2–1.7)
1.4 (1.2–1.6)
0.8
MELD before LT, median (IQR)
19 (14–23)
19.5 (14–22)
0.8
SLD, steatotic liver disease; AST, aspartate transaminase; ALT, alanine transaminase; MELD, model for end-stage liver disease. †Including metabolic liver disease and drug-induced liver disease that are not fulminant hepatitis. The Mann–Whitney U test was used for continuous variables and the exact Fisher for categorical variables.
